BioDelivery Sciences International (NASDAQ:BDSI) posted its quarterly earnings results on Thursday. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.04, Morningstar.com reports. BioDelivery Sciences International had a negative net margin of 103.01% and a negative return on equity of 278.79%. The business had revenue of $14.16 million during the quarter, compared to analyst estimates of $14.21 million.

Shares of NASDAQ BDSI traded up $0.09 during trading hours on Friday, hitting $3.78. 688,322 shares of the stock were exchanged, compared to its average volume of 731,159. The company has a quick ratio of 2.90, a current ratio of 3.16 and a debt-to-equity ratio of 1.21. The firm has a market cap of $224.54 million, a PE ratio of -9.69 and a beta of 0.09. BioDelivery Sciences International has a 12 month low of $1.70 and a 12 month high of $4.14.

In related news, Director Francis E. Odonnell, Jr. sold 151,039 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The shares were sold at an average price of $2.84, for a total transaction of $428,950.76. Following the completion of the transaction, the director now owns 520,482 shares in the company, valued at approximately $1,478,168.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $3.84, for a total transaction of $30,720.00. Following the transaction, the director now owns 522,187 shares of the company’s stock, valued at approximately $2,005,198.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 175,039 shares of company stock valued at $503,991. 13.26% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of BDSI. Bank of Montreal Can bought a new position in shares of BioDelivery Sciences International during the 2nd quarter worth approximately $138,000. Royce & Associates LP raised its stake in shares of BioDelivery Sciences International by 19.1% during the 2nd quarter. Royce & Associates LP now owns 2,200,800 shares of the specialty pharmaceutical company’s stock worth $6,492,000 after acquiring an additional 352,200 shares in the last quarter. BlackRock Inc. raised its stake in shares of BioDelivery Sciences International by 2.7% during the 2nd quarter. BlackRock Inc. now owns 1,190,286 shares of the specialty pharmaceutical company’s stock worth $3,512,000 after acquiring an additional 30,991 shares in the last quarter. PNC Financial Services Group Inc. bought a new position in shares of BioDelivery Sciences International during the 2nd quarter worth approximately $148,000. Finally, Cortina Asset Management LLC bought a new position in shares of BioDelivery Sciences International during the 2nd quarter worth approximately $5,629,000. Hedge funds and other institutional investors own 46.10% of the company’s stock.

Several equities research analysts have recently commented on BDSI shares. Zacks Investment Research upgraded shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a report on Monday, July 23rd. Cantor Fitzgerald restated a “buy” rating and issued a $4.50 price target on shares of BioDelivery Sciences International in a report on Thursday, August 9th. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of BioDelivery Sciences International in a report on Friday, August 10th. Finally, Janney Montgomery Scott boosted their price target on shares of BioDelivery Sciences International to $5.00 and gave the company a “buy” rating in a report on Friday, November 2nd. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $4.54.

TRADEMARK VIOLATION WARNING: “BioDelivery Sciences International (BDSI) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS” was first posted by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/11/10/biodelivery-sciences-international-bdsi-releases-quarterly-earnings-results-beats-expectations-by-0-04-eps.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Article: Day Trading

Earnings History for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.